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a b s t r a c t
Replication competent adenovirus (RC-Ad) vectors mediate robust transgene expression by virtue of
amplifying transgenes by replication but also put patients at a risk of frank adenovirus infection. In
contrast, E1-deleted replication defective Ad (RD-Ad) vectors are safer but produce substantially less
transgene product. To generate a robust, but safer adenoviral vector, we created a “single cycle”
adenovirus (SC-Ad) vector that replicates its genome and transgene, but that does not cause adenovirus
infections by deleting the capsid cement protein IIIa in low seroprevalence adenovirus serotype 6. Ad6-
ΔIIIa can be produced in IIIa-expressing cell lines. In normal cells, Ad6-ΔIIIa replicates its genome and
transgene but fails to package its DNA or form mature virus. SC-Ad and RC-Ad expressed transgenes
hundreds of times higher than RD-Ad in human and mouse cells in vitro and in vivo in mice. These data
suggest that SC-Ads may be safer amplifying vectors for vaccine and therapeutic applications.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Adenoviruses (Ads) are non-enveloped viruses carrying
double-stranded DNA genomes (reviewed in (Campos and Barry,
2007)). Ad capsids are composed of seven proteins: hexon (II),
penton base (III), ﬁber (IV), IIIa, VI, VIII and IX (Campos and Barry,
2007) (Fig. 1A). The major capsid proteins include hexon, penton
base, and ﬁber that are present in 720, 60, and 36 copies per virion
and make up the majority of the virion surface. Minor capsid
proteins are IIIa, VI, VIII, and IX. Protein IIIa is a 63 kDa protein
present at 60 copies per virion. IIIa was originally assigned to a
position adjacent to the viral peripentonal hexons where it was
thought to “cement” the interlocking facets together (Stewart
et al., 1993) (Fig. 1A). While this may be its function, its position
on the virion is still debated (Liu et al., 2010; Reddy et al., 2010).
Ads were one of the ﬁrst virus vector systems created for gene
therapy or gene-based vaccine uses (Campos and Barry, 2007).
A fully replication competent Ad (RC-Ad) gene-delivery vector
poses signiﬁcant safety concerns, due to the possibility of
uncontrolled viral replication and causing adenoviral disease.
To circumvent this, replication defective vectors (RD-Ad) were
developed by deleting pivotal E1 genes to drastically reduce viral
genome replication, protein expression, and the production
of progeny virions. Delivery of one RD-Ad to a cell delivers one
copy of the transgene resulting in the expression of “1X” protein.
In contrast, a replication-competent RC-Ad can replicate the same
gene 100,000-fold to increase transgene expression and immune
responses. When tested as HIV vaccines in macaques, RC-Ads are
superior to RD-Ads, particularly by the oral route (Demberg et al.,
2007; Demberg and Robert-Guroff, 2009; Gomez-Roman et al.,
2006a; Gomez-Roman et al., 2006b; Gomez-Roman et al., 2006c;
Hidajat et al., 2009; Malkevitch et al., 2003; Morgan et al., 2008;
Patterson et al., 2004; Peng et al., 2006; Peng et al., 2005; Zhao
et al., 2003; Zhao et al., 2005).
While RC-Ads are more potent, they run the real risk of causing
adenovirus infections. In contrast, a “single cycle” adenovirus that
retains the ability to replicate its genome (and transgene), but is
blocked from producing functional progeny virions may take
advantage of transgene replication, but avoids the real risks of
adenoviral infection. To test this concept, we deleted protein IIIa in
species C adenovirus serotype 6 (Ad6) to create a single-cycle
adenovirus (SC-Ad). In this work, we compare genome replication,
virion production, infectivity, and the ability to express transgenes
between RD-Ad6, SC-Ad6, and RC-Ad6.
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Results
Production of Ad6-ΔIIIa
Protein IIIa is a minor cement protein thought to be located
near the peripentonal hexons of the Ad capsid (Liu et al., 2010;
Reddy et al., 2010) (Fig. 1A). The protein has roles in late stage
virus maturation and serotype-speciﬁc genome packaging. Since
these are steps that occur only at the later stages of capsid
assembly after genome replication, we targeted IIIa as a potential
viral modiﬁcation to generate a SC-Ad.
The majority of humans have pre-existing immunity to con-
ventional adenovirus serotype 5 (Ad5) (Abbink et al., 2007). Ad6 is
also a species of C adenovirus like Ad5 (Weaver et al., 2009;
Weaver et al., 2013). However, Ad6 has lower seroprevalence than
Ad5 and is not cross-neutralized by Ad5 antibodies. For these
reasons, we deleted the gene for IIIA in Ad6 rather than Ad5.
The IIIa gene was deleted in an E3-deleted Ad6 plasmid
carrying a green ﬂuorescence protein–luciferase fusion protein
(GFPLuc) by homologous recombination in bacteria (Campos
and Barry, 2004) (Fig. 1B). To provide IIIa in trans, the Ad6 IIIa
cDNA was used to generate a 293 stable cell line (293-IIIa).
IIIa expression was conﬁrmed by western blot (data not
shown). Ad6-ΔIIIa was rescued by transfection and propagation
in 293-IIIa cells. Control Ad6 vectors with the same E3 deletion
and GFPLuc transgene cassette were generated, including RD-Ad6
(with E1 deleted) and RC-Ad6 (with intact E1 and IIIa genes)
(Fig. 1B).
Ad6-ΔIIIa replicates its genome like RC-Ad6
To determine if Ad6-ΔIIIa was still able to replicate its genome,
human A549 cells were infected with 1000 viral particles per cell
(vp/cell) of it and RD-Ad and RC-Ad6. Two hours later, bound and
excess virions were removed with trypsin and plated in 6 well
dishes. To detect viral genomes, total DNA was isolated prior to
real time quantitative PCR against the hexon gene at 2 or 24 h
(Fig. 2A). At 2 h, all three vectors had similar low levels of viral
genomes associated with the cells. After 24 h, the viral genome
copies for Ad6-ΔIIIa and RC-Ad6 increased 2000 to 3000-fold
whereas RD-Ad6 copies did not amplify (Fig. 2A).
Ad6-ΔIIIa kills infected cells but does not produce infectious progeny
To determine if Ad6-ΔIIIa kills cells at a similar rate as RC-Ad6,
cell viability was assessed by MTT assay. Cells infected with RD-
Ad6 showed minimal loss of viability through day 4. Cells infected
with Ad6-ΔIIIa or RC-Ad6 began to die by day 2, with increasing
loss of viability through day 4 (Fig. 2B). There was no signiﬁcant
difference in viability between Ad6-ΔIIIa and RC-Ad6. While both
viruses ultimately killed the cells, Ad6-ΔIIIa did not produce
infectious progeny virions from A549 cells as assessed by viral
burst assay (Fig. 2C).
Ad6-ΔIIIa produces immature, empty virus particles
It was unclear whether Ad6-ΔIIIa could produce a virus particle
in the absence of the IIIa protein. To test this, 293 and 293-IIIa
Fig. 1. Adenovirus capsid and schematic of Ad genomes expressing GFP–Luc fusion
protein. A) Diagram of adenovirus capsid. B) Schematic of Ad vectors used in the
study. CMV-cytomegalovirus; ITR-Inverted terminal repeat.
Fig. 2. Characterization of Ad6 vectors in A549 cells. A549 cells were infected with
RD-, SC-, or RC-Ad6 at 1000 vp/cell. A) Total DNA was collected from cell lysates at
2 and 24 h post-infection. Viral DNA was quantiﬁed by qPCR with primers
amplifying Ad6 hexon. B) MTT reagent was added to infected cells at the indicated
time points. Developing reagent was added after 3.5 h and A595/620 was
measured. Values represent % viability compared to mock. C) Total cell lysates
were collected at the indicated time points. Samples were freeze-thawed 3 times
and burst was quantiﬁed by TCID50 assay.
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cells were infected with Ad6-ΔIIIa at 500 vp/cell. 2 days later, the
infected cells were analyzed by transmission electron microscopy
(TEM) or were puriﬁed on CsCl gradients (Figs. 3 and 4). For TEM,
a non-speciﬁc stain for electron dense regions was used. In
addition to staining protein, cellular and viral DNA is darkly
stained as well. TEM revealed a mixture of lightly and darkly
stained particles in the nuclei of 293-IIIa cells (Fig. 3A and C). In
the absence of IIIa in 293 cells, only lightly stained particles were
observed (Fig. 3B and D). The major difference in the staining is in
the internal core of the particle, where viral DNA would typically
be packaged.
When the Ad6-ΔIIIa infected 293-IIIa cells were lysed and
separated on CsCl gradients, an upper “light” band and a lower
“heavy” band corresponding to intermediate and mature particles,
respectively (Fig. 4A). In contrast, lysates from Ad6-ΔIIIa infected
293 cells produced only a light CsCl band (Fig. 4B). Spectro-
photometry at 260 and 280 nm and agarose gel electrophoresis
indicated that the heavy band particles from 293-IIIa cells con-
tained viral DNA, whereas the light intermediate particles from
both cell lines did not contain viral genomic DNA (Fig. 4D).
Protein content of Ad6-ΔIIIa particles
The light and heavy bands from the CsCl gradients were separated
on 10% SDS-PAGE and the gel was stained with Coomassie blue to
detect viral proteins (Fig. 4C). The heavy bands contained mature
processed proteins VI and VII. In contrast, the light band particles
from both 293-IIIa and 293 cells contained no mature proteins VI or
VII. Instead, they contained only the precursor proteins pVI and pVIII
indicating that the light band particles were immature intermediate
adenoviral virions. As expected, Ad6-ΔIIIa light band particles pro-
duced from 293 cells contained no protein IIIa.
SC-Ad6 expresses more transgene product than RD-Ad6 in vitro
These data indicated that Ad6-ΔIIIa behaved like a single-cycle
adenovirus, so is hereafter referred to as SC-Ad6. The ultimate
goal of the single cycle Ad vector is to express higher levels of
transgene in cells compared to replication defective Ad vectors.
The vectors in this study all encode GFP–Luc so expression
could be easily monitored over time. Human A549 cells were
infected at 1000 vp/cell, and luciferase expression was measured
at the indicated time points (Fig. 5A). RD-Ad6 mediated low
but increasing expression of luciferase. In contrast, cells infected
with SC-Ad6 and RC-Ad6 produced 100-fold higher levels of
luciferase than RD-Ad6 (po0.0001 by repeated measures two-
way ANOVA).
SC-Ad6 replicates and expresses more transgene product
than RD-Ad6 in mice
Mouse Hepa 1-6 cells are permissive for Ad replication
and infection (Nagayama et al., 2003). Hepa 1-6 cells were infected
at 1000 vp/cell and luciferase expression was monitored over time
(Fig. 5B). In this case, luciferase expression increased over 2 days
with SC-Ad and RC-Ad luciferase levels being 20 and 30 times
higher than RD-Ad6 at this time point. In contrast to human A549
cells, luciferase expression in the mouse cells peaked at day 2 but
then rapidly declined to RD-Ad6 levels by day 5.
To characterize SC-Ad6 in vivo, groups of 5 BALB/c mice
were injected intravenously with 31010 vp of the indicated
viruses and livers were harvested on days one through four. qPCR
of liver samples demonstrated that RD-Ad6 genome levels
remained relatively constant over four days (Fig. 6A). In contrast,
qPCR demonstrated that the genome copies of both SC-Ad6 and
Fig. 3. SC-Ad6 particles of varied maturity formed in presence and absence of IIIa 293 (A, C) or 293-IIIa (B, D) were infected with SC-Ad6 at 500 vp/cell. After 2 days, cells
were collected and divided. 5106 cells were ﬁxed and imaged by TEM. Images magniﬁed 110,000x (A, B) and 220,000x (C, D).
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RC-Ad6 were higher at all time points with an apparent peak at
2 days. At this peak, SC-Ad6 genome copies were 40-fold higher
than RD-Ad6 while RC-Ad6 genomes were 125 times higher.
SC-Ad ampliﬁes transgene expression in vivo in mice when compared
to RD-Ad
Liver samples that were collected for qPCR were also tested for
luciferase activity (Fig. 6B). These data showed luciferase activity
peaking at day 2 in the mice and declining through day 4.
Consistent with genome ampliﬁcation, SC-Ad and RC-Ad ampliﬁed
transgene expressions above that mediated by the replication-
defective vector. In this case, SC-Ad6 and RC-Ad6 mediated 40-
and 300-fold higher luciferase activity than RD-Ad in the livers,
respectively.
SC-Ad and RC-Ad express more transgene product at lower
multiplicities of infection than RD-Ad in primary human airway
epithelia cells
To determine how the vectors might behave in normal human
cells, primary human small airway epithelial cells (HSAECs) were
infected at varied multiplicities of infection with the GFPLuc
expressing vectors and the cells were analyzed by microscopy
48 h later (Fig. 7). RD-Ad6 transduced most cells in the well at
virus to cell ratios of 3.3103 vp/cell. In contrast, both SC-Ad6 and
RC-Ad6 generated at 33-fold lower multiplicities of infection.
Discussion
Human adenovirus vectors have shown potential for develop-
ment as therapeutics for cancer, infectious disease, and genetic
diseases. However, scale up into larger animals and humans and
safety concerns have been signiﬁcant hurdles for traditional repli-
cation defective and replication competent vectors. To overcome
Fig. 4. SC-Ad6 particles do not contain proteins VI, VII or IIIa. Infected 293-IIIa (A) and 293 (B) cells were separated on CsCl gradients. C) Puriﬁed virus particles were treated
with SDS and run on a 10% SDS-PAGE, and stained with Bio-Safe Coomassie. D) Puriﬁed virus particles were treated with SDS and separated with agarose gel electrophoresis.
A260/280 ratios for 293-empty: 1.04, 293-IIIa-empty: 1.11, 293-IIIa-mature: 1.26.
Fig. 5. Luciferase expression of Ad vectors in vitro. Human A549 (A) or mouse Hepa
1-6 (B) cells were infected at 1000 vp/cell. Luciferase expression was measured
using Bright-Glo luciferase reagent at the indicated time points. Luminescence was
measured using a Beckman Coulter plate reader.
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these challenges, we engineered “single cycle” replicating adeno-
virus 6 by deleting cement protein IIIa from the viral genome. SC-
Ad6 effectively undergoes all of the early Ad life cycle events
including early gene transcription and genome replication. The
remaining late genes are transcribed and translated but in the
absence of IIIa only empty, non-infectious virus particles are
produced.
This vector could have beneﬁts over traditional replication
defective and replication competent vectors. With RD-Ad6 infec-
tion, a low, but persistent level of luciferase protein is expressed
both in vitro and in vivo. Due to the presence of E1 and other early
genes, SC-Ad6 replicates its own genome along with any transgene
it carries. In this proof of principle, SC-Ad6 produced signiﬁcantly
more luciferase than RD-Ad6 in vitro and in vivo in human and
mouse cells.
When the vectors were compared in human and mouse cells,
the SC-Ad6 and RC-Ad6 were both able to replicate their genomes.
This was interesting in part because it is generally accepted that
adenoviruses do not replicate well in mice (Thomas et al., 2007).
While it is true that infectious viruses are poorly replicated in
mice, genome replication appears functional as demonstrated by
qPCR. These data are consistent with early data showing that Ad5,
another species C adenovirus, also ampliﬁes in mouse liver after
intravenous injection (Duncan et al., 1978). While the replication-
competent Ad6 vectors did replicate their genomes and amplify
transgene expression, these ampliﬁcations were approximately
50-fold less efﬁcient than was observed in human cells. It should
also be noted that luciferase expression in vitro and in vivo
decreased after 2 days in mouse cells but not in human cells. It
is unclear exactly why expression declined in mouse cells; how-
ever, this may be due to defects in the ability of human adeno-
viruses to complete the viral life cycle after genome replication. In
particular, human Ads may fail to express late capsid components
which may contribute to instability of newly synthesized viral
genomes (Eggerding and Pierce, 1986). It is also possible that
reduce late gene expression in mouse cells may perturb mouse
cells and not humans cells to reduce expression. This is suggested
in part by more rapid cell death in mouse Hepa1-6 cells than A549
cells even though SC- and RC-Ads replicate their genomes mark-
edly higher in the human cells. From this, mice can be used to
model single-cycle or replication-competent Ad6 but this model
likely underestimates the impact of genome and transgene repli-
cation that may occur in non-human primates and humans.
SC-Ad6 transgene expression was quite comparable with RC-
Ad6 in human and mouse cell lines when tested in vitro. In
contrast, in vivo, SC-Ad6 replication was 3-fold less efﬁcient than
RC-Ad6 and luciferase activity was 7-fold lower. These data
suggest that factors present in vivo may modulate SC-Ad6 activity.
These may be related to differences in genome packaging effects
on innate immune responses or perhaps due to abortive second
cycle infection by RC-Ad6 but not SC-Ad6. In contrast, when the
vectors were tested in vitro on primary human airway cells, both
SC-Ad and RC-Ad vectors generated markedly higher transduction
at low multiplicities of infection. Notably, SC-Ad6 did not generate
infectious virions making it appealing as safer replicating adeno-
virus vaccine than fully competent RC-Ads.
While SC-Ad avoids a burst of infectious viruses from trans-
duced cells, it does ultimately kill the initial target cells like RC-Ad.
Therefore, these ﬁrst infected cells are sacriﬁced to produce more
transgene product. This makes SC-Ads less safe than RD-Ads but
safer than RC-Ad6. This “Goldilocks” situation will require SC-Ads
to be used under conditions that strike the right cost/beneﬁt ratio.
Sacriﬁcing transduced cells is obviously not feasible for gene
replacement therapy, so SC-Ads are not likely candidates for this
type of therapy. In contrast, sacriﬁcing mucosal cells for vaccines
or tumor cells for cancer gene therapy may have merit.
Fig. 7. GFP-mediated transduction of primary human airway epithelial cells.
HSAECs were infected at the indicated vp/cell ratios and the monolayers were
imaged on an inverted microscope 48 h later.
Fig. 6. Genome ampliﬁcation and luciferase expression in BALB/c mice. Groups of
30 female mice were injected with 31010 vp intravenously. At the indicated time
points, liver samples were collected. (A) Total DNA was isolated and viral genomes
were quantiﬁed by qPCR. N¼15/virus group for day one, n¼5/virus group on days
2–4. (B) Samples were homogenized and Bright-Glo luciferase reagent was added
at 1:1 ratio. Luminescence was measured using a Beckman Coulter plate reader.
N¼5/virus group/time point.
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In between these two extremes are using SC-Ads as gene-based
vaccines, particularly for mucosal or oral vaccination. Fully wild-
type RC-Ad4 and Ad7 adenoviruses have been used as oral
vaccines to protect military personnel from respiratory infections.
In this case, the vaccines must be delivered orally to avoid causing
the respiratory disease one seeks to avoid (Couch et al., 1963). Oral
RC-Ad delivery avoided the side effects of these wild viruses but
still allowed mucosal vaccination to occur to protect from later RC-
Ad respiratory infection. Therefore, RC-Ads applied to other sites
run the real risk of causing adenovirus infections. In contrast, the
SC-Ad vectors, can amplify antigen production during vaccination,
but avoid the risk of adenovirus infection. They may particularly
useful by the oral route, since most Ads are nearly quantitatively
destroyed by stomach pH and digestive enzymes (Cheng et al.,
2003). Therefore, RC-Ad4 and Ad7 vaccines were likely efﬁcacious
because they were able to amplify antigen production from the
reduced number of cells that were infected by this stringent route.
Proof of principle using RC-Ads safely in humans combined with
the safer proﬁle of SC-Ads, suggest these vectors may have utility
also for systemic and mucosal vaccines against cancer and infec-
tious agents.
Materials and methods
Cell culture
293 human embryonic kidney cells were purchased from
Microbix (Toronto, Ontario, Canada). A549 lung carcinoma and
mouse Hepa 1-6 cells were purchased from American Type Culture
Collection (ATCC, Manassas, VA). To produce 293-IIIa cells, the
entire IIIa gene from Ad6 was PCR ampliﬁed and inserted into the
plasmid pIRES-puro3 using BamHI and XhoI sites (Clontech,
Mountain View, CA). The IIIa gene is expressed from a CMV
promoter in a single transcript shared with an IRES-puromycin
resistance gene. pIRES-puro3-IIIa was transfected in 293 cells
using Polyfect reagent (Qiagen, Hilden, Germany), and cells were
selected with 2 mg/ml puromycin. Cells were maintained as a
mixed population, and IIIa expression was conﬁrmed by western
blot (data not shown). 293 cells were maintained in Dulbecco's
Modiﬁed Eagle Medium supplemented with 10% fetal bovine
serum (FBS; HyClone, Rockford, IL) and penicillin/streptomycin at
100 U/mL (Gibco). Primary human small airway epithelial cells
(HSAECs) were purchased from Lifeline Cell Technology (Frederick,
MD). HSAECs were maintained in BronchiaLife SAE Complete
Medium.
Adenoviruses
A human adenovirus 6 plasmid was produced as described
previously (Weaver et al., 2011), and genome modiﬁcations were
completed using homologous recombination in bacteria as in
Campos and Barry (2004). The E3 region of Ad6 was deleted by
replacing the entire E3 region with a zeocin resistance gene. First,
three PCR fragments were generated. The ﬁrst was a 500 base pair
product upstream of E3 and homologous to pVIII, the second a
zeocin resistance gene ﬂanked by short ﬂippase recognition target
(FRT) sites, and the third a 500 base pair product homologous
downstream to gene U. A single DNA fragment was generated by
overlapping PCR, which was recombined into pAd6. After recom-
bination the zeocin gene was removed by ﬂp recombinase in
bacteria. A CMV-GFP–Luciferase-LZL-SV40 polyA cassette expres-
sing a green ﬂuorescence protein–luciferase fusion was inserted by
ﬁrst digesting pAd6 with PshAI and SwaI to make a smaller Ad6
plasmid with a unique MfeI site between the ﬁber and E4 open
reading frames (pAd6-PshSwa). The CMV-GFPLuc-SVA gene was
ampliﬁed by PCR, adding BsaI sites on each end with compatible
overhangs for MfeI. CMV-GFPLuc-SVA was inserted in pAd6-
PshSwa by direct ligation. pAd6-PshSwa-GL was linearized and
recombined with pAd6-ΔE3. For RD-Ad generation, the E1 region
was deleted by overlapping PCR of three fragments, one a 500bp
region homologous to the region upstream of E1A, the second a
blasticidin (BSD) resistance gene, and the third a 500 bp region
homologous to pIX. The entire E1A/E1B region was removed by
replacement with the BSD resistance gene by homologous recom-
bination with pAd6-ΔE3-GL. For SC-Ad generation, the IIIa gene
was deleted by overlapping PCR of three fragments, one a 500 bp
region homologous to 52K, the second a zeocin resistance gene
ﬂanked by FRT sites, and the third a 500 bp region homologous to
pII. The entire IIIa gene was replaced by the zeocin resistance gene,
which was then removed with ﬂp recombinase. E3 was deleted
and GL was inserted by digesting pAd6-ΔE3-GL with PshAI and
RsrII, and the E3 deletion and GL were recombined into pAd6-
ΔIIIa. Viruses were rescued in 293 cells or 293-IIIa cells and
puriﬁed by double CsCl banding. Virus was desalted in 10%
sucrose/KPBS. Virus particle concentration was determined by
OD260. A260/280 ratios for each vector were: RD-Ad6-GL:1.3,
SC-Ad6-GL:1.26, and RC-Ad6-GL:1.33.
in vitro vector genome quantiﬁcation
3105 cells were plated in 6 well plates and infected at 1000
virus particles (vp)/cell. Two hours after infection, 1 ml of trypsin
was added to cells. Detached cells were washed once with 5 ml of
5% FBS/DMEM. Cells were resuspended in 2 ml of 5% FBS/DMEM,
and were plated in 6 well plates. After 24 h, cells were collected
from plates with cell scrapers. Total DNA was isolated at 2–24 h
after infection using the DNeasy Blood and Tissue kit according to
manufacturer's protocol (Qiagen) with an RNase A digestion.
Vector genomes were quantiﬁed using qPCR with primers against
adenovirus hexon.
Quantitative real time PCR (qPCR)
Concentration of DNA samples was determined by OD260 and
diluted to 20 ng/μl. Real-time PCR was performed using the
Applied Biosystems Prism 7900HT sequence detection system
with SDS 2.3 software. Each well contained 10 μl Sybr Green
(Applied Biosystems, Warrington, UK), 3.8 μl H2O, 0.6 μl of 10 μM
F Primer, 0.6 μl of 10 μM R Primer, and 5 μl sample (i.e., 20ng DNA/
well).
Cell viability assay
5103 A549 cells were plated in 96 well plates and infected at
1000 vp/cell. At the indicated time points, 500 ml MTT (5 mg/ml)
was added to the wells, and incubated 3.5 h at 37 1C. Media was
removed and MTT developing reagent was added. After 15 min,
A595 with A620 reference was read using the Beckman Coulter
DTX 880 Multimode Detector system.
in vitro virus burst assay
2106 A549 cells were placed in a T75 ﬂask and infected at
1000 vp/cell. 1 h post-infection, 3 mL trypsin was added to cells.
Cells were washed once with 10 ml of 5% FBS/DMEM, and
resuspended to a concentration of 2105 cells/ml. 1 ml was
collected and stored at 80 1C, and 1 ml was plated in each of
3 wells of a 6 well plate. Cells and supernatant were collected at
indicated time points and stored at 80 1C. Cells were freeze-
thawed 3 times and virus burst was quantiﬁed by TCID50 assay.
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Transmission electron microscopy
293 or 293-IIIa cells were infected with SC-Ad6 at 500 vp/cell.
Cells were collected two days later and resuspended in 4%
paraformaldehyde, 1% gluteraldehyde. Samples were processed
and sectioned by the Electron Microscopy Core Facility (Mayo
Clinic, Rochester, MN). Images were captured on a Philips CM10
Transmission Electron Microscope, equipped with a Gatan digital
camera.
SDS-PAGE and Coomassie blue staining
293 or 293-IIIa cells were infected with SC-Ad6 at 500 vp/cell.
Cells were collected at two days, and virus was puriﬁed by single
CsCl banding and desalted in 10% Sucrose/KPBS. Samples were
boiled in 4x Laemelli's buffer, and run on a 10% tricine SDS-PAGE
gel. The gel was stained with Bio-Safe Coomassie Stain (BioRad,
Hercules, CA).
Agarose gel electrophoresis of puriﬁed particles
Equal numbers of puriﬁed virus particles were combined with
0.2% SDS at a Virus:PBS:SDS ratio of 1:1:2. Samples were combined
with 6x DNA loading dye, and separated on a 0.8% agarose gel
containing GelRed nucleic acid stain (Biotium, Hayward, CA).
in vitro luciferase assay
To quantify luciferase expression 1103 cells were plated in
black-walled 96-well plates and infected at 1000 vp/cell. At
indicated time points, Bright-Glo luciferase reagent (Promega,
Madison, WI) was added at a 1:1 ratio and luciferase activity
was measured using the Beckman Coulter DTX 880 Multimode
Detector system.
Animals
Female BALB/c mice were purchased from Harlan Sprague-
Dawley (Indianapolis, IN). They were housed in the Mayo Clinic
Animal Facility under the Association for Assessment and Accred-
itation of Laboratory Animal Care (AALAC) guidelines with animal
use protocols approved by the Mayo Clinic Animal Use and Care
Committee. All animal experiments were carried out according to
the provisions of the Animal Welfare Act, PHS Animal Welfare
Policy, the principles of the NIH Guide for the Care and Use of
Laboratory Animals, and the policies and procedures of Mayo
Clinic. Mice were injected intravenously with 31010 vp in
100 μL PBS.
DNA isolation from mouse liver tissues
Liver samples were collected and washed with PBS. Total DNA
was isolated from liver samples using a Maxwell 16 DNA Puriﬁca-
tion Kit (Promega, Madison, WI).
Luciferase expression of mouse liver tissues
Liver samples were collected and washed with PBS. Samples
were homogenized in T-Per Reagent containing protease inhibitors
(Fisher Scientiﬁc, Rockford, IL). Homogenized tissue and Bright-Glo
luciferase reagent (Promega, Madison, WI) were added at a 1:1
ratio of volume. Luciferase activity was measured using the Beck-
man Coulter DTX 880 Multimode Detector system.
Data Analysis
Graphs and statistical analyses were performed using Prism
Graphical software.
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